| Thursday May 18, 2006 |
|
|
|
|
| 7:00 - 8:00 |
Continental Breakfast & Registration
|
|
|
|
| 8:00 - 8:30 |
Welcome: The Global Neurotech Industry 2006
|
|
NeuroInsights reveals updated proprietary market data, and industry trends.
Zack Lynch
Managing Director, NeuroInsights
|
|
|
|
|
| 8:30 - 9:15 |
Investing in Neurotech
|
|
A diverse panel of neurotech investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are alternative fund raising strategies? What are the benefits and risks of business models in devices, pharmaceuticals, and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?
Moderator: Casey Crawford Lynch
Managing Partner, NeuroInsights
Managing Director, Science Futures
Mark Cochran, PhD
Managing Director, NeuroVentures Capital
Carl Goldfischer, MD
Managing Director, Bay City Capital
Roger Quy, PhD
General Partner, Technology Partners
Matthew Perry
Portfolio Manager, Biotechnology Value Fund
|
|
|
|
|
| 9:15-10:15 |
The Memory Market: Alzheimer's and Cognitive Therapeutics |
|
As the population ages, the market for memory, cognitive impairment, and Alzheimer’s treatments is exploding. What are the latest strategies for treating memory decline? While the FDA has approved the category mild cognitive impairment (MCI), is there a clear path to patient identification and drug approval? Are we closer to curing Alzheimer’s disease? What are the technical, preclinical and clinical challenges? How are companies leveraging expertise and leads into other indications?
Moderator: Gary King, PhD
Senior Director, Licensing, Bristol-Meyers Squibb
J. Donald deBethizy, PhD
President & CEO, Targacept
Jeffrey Ostrove, PhD
President & CEO, Ceregene
Rodney Pearlman, PhD
President & CEO, Saegis Pharmaceuticals
David Summa
President & CEO, Acumen Pharmaceuticals
|
|
|
|
|
| 10:15 - 10:30 |
Networking and Refreshment Break |
|
|
|
| 10:30 -11:15 |
Corporate Partnering and Licensing in Neurotech |
|
Big pharma, biotech and medtech increasingly are looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and partnering? Is there a new model for partnerships emerging? Is Big pharma still a good partner for neurotech? Can small neurotech companies team up to commercialize products?
Moderator: Frank Eeckman, MD, PhD
Neurotech Insights, Centient
Dr. Christine de los Reyes
Senior Director, Licensing & Development, Pfizer
Xavier Lataste
Head of Neuroscience, Business Development & Licensing, Novartis
Dr. Kumar Srinivasan
Senior Director, Licensing, Global Business Development, Wyeth
|
|
|
|
|
| 11:15 -12:00 |
Advances in Brain Imaging and NeuroInformatics |
|
The quest to develop increasingly more effective neurotherapeutics and diagnostics depends upon continuously higher quality molecular, cellular and systems level information about the brain. The goal of neuroinformatics is to provide standardized, quantitative datasets that allow the rapid comparison of patient profiles against normative data, including genetic, brain imaging, lifestyle and symptom information. How are neuroinformatics databases currently being used to improve drug development? What are the current capabilities and limitations of neuroimaging technologies (MRI, fMRI, CT, & PET)? Are there advances in imaging and informatics on the horizon that could dramatically impact therapeutic development or diagnostics?
Richard Haiduck
Brain Resource Company
Allan Jones, PhD
Director, Allen Institute for Brain Science
John Schenck, MD, PhD
NeuroImaging Research, GE Global Research Center
|
|
|
|
|
| 12:00 -1:30 |
Luncheon Keynote
|
|
"Accelerating the Decade of Translation"
Lore Harp McGovern
Co-founder, McGovern Institute for Brain Research at MIT
|
|
| 1:30 - 2:30 |
The Future of Neuropsychiatry and Specialty Pharmaceuticals |
|
Anxiety, depression, schizophrenia and other neuropsychiatric illnesses represent a large portion of the neuropharmacuetical market. How is polypharmacy, the use of multiple drugs to treat an illness, playing a role in drug development strategies? How and why are companies creating new market categories for their compounds? Are there advantages in neuropsychiatry for “multiple shots on goal?” How are companies using in-licensing and out-licensing to compete in these markets? What are the unique investment risks and payoffs?
Moderator: Sam Barondes, MD
Director, Center for Neurobiology & Psychiatry, UCSF
Matthew Fust
Sr. VP & Chief Financial Officer, Jazz Pharmaceuticals
Michael Kauffman, MD, PhD
President & CEO, Predix
Jim Schoeneck
CEO, BrainCells Inc.
Rick Stewart
CEO, Amarin Corporation
|
|
|
|
|
| 2:30 - 3:15 |
Spinning Neurotech out of the Lab |
|
|
Industry relies on institutes and universities for basic research which will eventually lead to breakthrough treatments. Learn new models and effective strategies for technology transfer and industry collaboration from leading edge organizations in neurotech. How do serial entrepreneurs bridge the divide between basic research and commercial solutions? What is the cutting edge science that will influence the next generation of products?
Moderator: Bruce Scott
President & CEO, Intellectual Licensing Group
Steven Gerrish
Director of Business Development
Purdue Research Foundation
Karoly Nikolich, PhD
Executive Director, Neuroscience Institute at Stanford
Wendye Robbins, MD
President & CEO, Limerick NeuroScience
Selena Bartlett
Director, Medications Development
Ernst Gallo Clinic & Research Center
|
|
|
|
| 3:15 - 3:30 |
Networking and Refreshment Break |
|
|
|
| 3:30 - 4:30 |
Neurodevices: Is Neuro the next Cardio? |
|
|
Neurostimulation devices are gaining ground in markets like pain and Parkinson's disease, while new approvals and innovative startups are showing that neurostimulation can be applied to markets like depression, epilepsy, obesity, stroke, spinal cord injury, urinary incontinence, and others. Where are the best opportunities for devices to compete with or displace drugs? While medical devices have traditionally had a faster path to market, does this apply for neurodevices too? Can neurodevices compete in cost and efficiency? What are the current reimbursement issues for neurodevices? |
|
|
Moderator: Jim Cavuoto
Editor, Neurotech Reports
Lothar Krinke, PhD
Senior Director, Business Development,
Medtronic Neurological
John Dobak
Founder, Leptos Biomedical
Bruce Shook
President & CEO, Neuronetics
Tim Surgenor
CEO, Cyberkinetics
|
|
| 4:30 - 5:30 |
Neuroregeneration: Stem Cells and Other Strategies |
|
The regeneration or replacement of nerve cells is the holy grail of neurological disease therapy. What is the state of innovative therapies to promote neuronal regeneration? What is a realistic time frame for product candidates to begin reaching the clinic?
Moderator: David Ewing Duncan
Founder and Editorial Director, BioAgenda
Anders Haegerstrand, MD, PhD
Chief Scientific Officer, NeuroNova Pharmaceuticals
Johnathan Kil, MD
President & CEO, Sound Pharmaceuticals
Martin McGlynn
President & CEO, StemCells, Inc
Peter Mountford, PhD
President & CEO, StemCell Sciences
|
|
5:30 - 7:00 Wine Tasting Reception |
